Leukemia and Lymphoma

Updates on Waldenström macroglobulinemia treatment formed by an international consensus panel were recently finalized and published in The Lancet Haematology.

Break Through Cancer, a collaborative research effort between 5 top US academic cancer centers, aims to pursue solutions to some of the most difficult challenges in cancer research.

Hypertension, anemia, and infection were the most common adverse events associated with mantle cell lymphoma (MCL), while hepatotoxicity, stroke, and renal failure were the costliest per patient.

Tanya Siddiqi, MD, director of the chronic lymphocytic leukemia program at Toni Stephenson Lymphoma Center provides insights on what the arrival of liso-cel could mean in the treatment landscape.

Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine.

The newly approved expanded label includes data from the final analysis of the phase 3 iNNOVATE study of ibrutinib plus rituximab vs rituximab alone.

Using CRISPR, researchers were able to repeat the step-by-step conversion of a normal cell into a malignant one in acute myeloid leukemia (AML).

Patients with mantle cell lymphoma (MCL) who discontinue acalabrutinib may have different outcomes depending on why they stopped and their eligibility for other therapies.

Results from a new clinical trial suggest that discontinuation of tyrosine kinase inhibitors (TKIs) is safe, feasible and is associated with improvements in patient-related outcomes (PROs) in chronic myeloid leukemia (CML).

A CAR T-cell therapy that promises fewer side effects, and possibly lower hospital costs, wins approval after lengthy delays.

The novel, first-in-class, small molecule prompted high rates of clinical response and molecular remission in patients with oligoblastic acute myeloid leukemia (AML).

Higher mortality rates were seen among patients with acute lymphoblastic leukemia (ALL) who were considered obese, in a recent study of patients treated at Mayo Clinic.

Despite outcome improvements for acute lymphoblastic leukemia (ALL), mortality rates remain high, with significant survival disparities seen between Black and White children.

Research findings from Mayo Clinic investigators demonstrate that diabetes did not increase the risk of death among patients with acute or chronic myeloid leukemia.

Tyrosine kinase inhibitor (TKI) therapy enables patients with chronic myeloid leukemia (CML) to reach life expectancies equivalent to the general population and treatment-free remission, but quality of life can deteriorate with treatment.

The Supreme Court reinstates the requirement on in-person pickup of pregnancy-ending medications; CMS releases numbers on 2020’s final week of Marketplace open enrollment; the FDA updates safety information for filgrastim (Neupogen).

A recent meta-analysis appearing in Journal of Cancer indicates a connection between minimal residual disease (MRD)–positive status and worse progression-free survival (PFS) and overall survival (OS) following induction and consolidation therapies.

Chimeric antigen receptor (CAR) T-cell exhaustion likely stems from chemotherapy prior to transplant, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

A small pilot study could point the way to a new option for patients with B-cell acute lymphoblastic leukemia (B-ALL) who experience cytokine release syndrome (CRS) that cannot be cured with the standard therapy.

Readers favored news about ibrutinib, the first chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma, and the effect of the pandemic on patients with chronic lymphocytic leukemia.

The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma, as a first-line and second-line therapy for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Both clinical and physician-based factors play a role in the risk of a patient with hematologic malignancies ending up in the ICU.

A new study may help clear up questions about the superiority of venetoclax with hypomethylating agents in patients who are deemed to be at high risk of treatment-related mortality.

A new study helps explain immunological factors that appear to have an impact on the success rate of mogamulizumab in patients with adult T-cell leukemia-lymphoma (ATL).

SEQUOIA arm D study results show better outcomes are possible for patients with 17p-deletion CLL, explained Ian Flinn, MD, PhD, director of lymphoma research at Sarah Cannon Research Institute.

Patients who previously were treated with rituximab saw durable responses when given single-agent ibrutinib, and the drug’s safety profile in a new study matches earlier findings.

Investigating circulating tumor DNA is a top priority for patients with diffuse large B-cell lymphoma, noted Michael R. Green, PhD, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.

Most patients who are diagnosed with acute myeloid leukemia are in middle or old age. The relatively small number who are diagnosed earlier in life can be subject to long-term health risks due to their treatment.

A new report finds including rituximab in first-line therapy for diffuse large B-cell lymphoma (DLBCL) results in better overall outcomes that more than offset the higher initial cost of therapy.

The risk of leukemia is higher for people living near petroleum industry complexes, according to a new analysis of 13 studies of the issue.